DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
PARSIFAL
A Randomized, Multicenter, Open-label, Phase II Trial to Evaluate Palbociclib in Combination with Fulvestrant or Letrozole in Endocrine-sensitive Patients with Estrogen Receptor (ER)[+]/HER2[-] Metastatic Breast Cancer:
PARSIFAL trial
BREAST
ASCO
2020
PARSIFAL
Palbociclib (P) in combination with fulvestrant (F) or letrozole (L) in endocrine-sensitive patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC): detailed safety analysis from a multicenter, randomized, open-label, phase II trial (PARSIFAL)
BREAST
SABCS
2020
OTHER
Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019
COVID-19
(Journal) European Journal of Cancer
2020
OTHER
Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon’s design
BREAST
(Journal) Contemporary Clinical Trials Communications
2020
KELLY
A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: KELLY study
BREAST
SABCS
2019
THELMA
Multicenter phase I trial of trastuzumab emtansine in combination with non-pegylated liposomal doxorubicin in HER2-positive metastatic breast cancer (THELMA study)
BREAST
ESMO
2019
NSABP FB-7
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
BREAST
(Journal) Breast Cancer Research
2019
REVERT
A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrin therapy: REVERT study
BREAST
SABCS
2019
OPHELIA
Effectiveness of olaparib plus trastuzumab in patients with HER2-positive, germinal BRCA-mutated or homologous recombination deficient advanced breast cancer. The OPHELIA study.
BREAST
ESMO
2019
TRASTYVERE
A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
BREAST
(Journal) Clinical and Translational Oncology
2019
MERIBEL
Phase II, multicenter, single-arm trial of eribulin as first-line therapy for patients with aggressive taxane-pretreated HER2[-] metastatic breast cancer: The MERIBEL Study
BREAST
(Journal) Clinical Breast Cancer
2019
NSABP FB-7
PD5-04: NSABP FB-7: A phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer.
BREAST
AACR
2019
Other MEDSIR related articles
"